DOCONEXENT
Other / unclassified targets PCSK9, PPARG via activation
Trials 37
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03101540 | Aug 2011 → May 2014 | major depressive disorder | William Coryell | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03101527 | May 2011 → Feb 2012 | major depressive disorder | William Coryell | Terminated | No outcome recorded Stop: Enrollment |
| Phase 16 trials | ||||||
| Phase 1 | NCT02103842 | Mar 2014 → Jul 2015 | muscular atrophy | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01903525 | Sep 2013 → Aug 2017 | traumatic brain injury, traumatic encephalopathy | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01563913 | Oct 2012 → Jun 2016 | Parkinson disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1 | NCT00325013 | Dec 2005 → May 2012 | colitis, primary sclerosing cholangitis | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00060749 | May 2003 → Dec 2007 | macular degeneration | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1 | NCT00014027 | Apr 2001 → Apr 2008 | — | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 1/23 trials · 1 met primary | ||||||
| Phase 1/2 | NCT03402789 | Jan → Jul 2024 | amblyopia | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04242004 | Oct 2019 → Mar 2020 | cognitive disorder | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00885313 | Mar 2009 → Apr 2010 | NAFLD1, abdominal obesity-metabolic syndrome, fibrotic liver disease, obesity disorder | Bambino Gesù Hospital and Research Institute | Completed | Met primary |
| Phase 28 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT03831178 | Aug 2019 → Dec 2024 overdue | breast cancer | AHS Cancer Control Alberta | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03613844 | Sep 2018 → May 2024 | — | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT02973360 | Mar → Sep 2017 | sickle cell disease | Micelle BioPharma Inc | Unknown | No outcome recorded |
| Phase 2 | NCT02514070 | Oct 2015 → Jul 2019 | — | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT01849250 | May 2013 → Jan 2016 | breast benign neoplasm, ductal breast carcinoma in situ, invasive breast carcinoma, lobular breast carcinoma in situ +1 | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT02690857 | May 2010 | cystic fibrosis | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT01976806 | Jun 2009 → Sep 2011 | gingivitis, periodontitis | Beth Israel Deaconess Medical Center | Completed | Met primary |
| Phase 2 | NCT00100230 | Sep 2004 → May 2012 | X-linked disease, retinitis pigmentosa | Retina Foundation of the Southwest | Completed | Missed primary |
| Phase 38 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT05796401 | Dec 2023 → Dec 2026 expected | psychotic disorder | Centre Hospitalier St Anne | Recruiting | No outcome recorded |
| Phase 3 | NCT03965988 | May 2018 → Nov 2028 expected | breath-holding Spells | Tanta University | Recruiting | Met primary |
| Phase 3 | NCT02626299 | Jun 2016 → Oct 2020 | — | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02098317 | Jan 2014 → May 2015 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01934777 | Oct 2013 → Oct 2014 | NAFLD1, abdominal obesity-metabolic syndrome, fibrotic liver disease, obesity disorder | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02005900 | Jun 2011 → Jun 2013 | HIV infectious disease, hyperlipidemia, hypertriglyceridemia | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00440050 | Feb 2007 → May 2009 | Alzheimer disease | Alzheimer's Disease Cooperative Study (ADCS) | Completed | Missed primary |
| Phase 3 | NCT01422317 | Sep 1995 → Dec 1997 | coronary artery disorder, myocardial infarction | Helse Stavanger HF | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04151758 | Jan 2019 → May 2021 | — | University of Milan | Unknown | No outcome recorded |
| Phase 4 | NCT01576783 | Apr 2012 → Apr 2017 | — | Sarah Keim | Completed | No outcome recorded |
| Phase 4 | NCT00449917 | Sep 2006 → Jul 2007 | — | PiLeJe | Completed | No outcome recorded |
| Phase 4 | NCT00290056 | Nov 2005 → Nov 2009 | cardiac rhythm disease, coronary artery disorder | Sheba Medical Center | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05191823 | Dec 2021 → Jun 2024 overdue | preterm premature rupture of the membranes | Sarah Keim | Enrolling by invitation | No outcome recorded |
| — | NCT01814527 | Jul 2013 → Jul 2017 | traumatic brain injury | East Carolina University | Completed | No outcome recorded |
| — | NCT00825994 | Nov 2008 → Jun 2009 | depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00976872 | Jan → Dec 2008 | — | Assaf-Harofeh Medical Center | Completed | No outcome recorded |
| — | NCT00360217 | Jan 2006 → May 2007 | coronary artery disorder, diabetes mellitus, hyperlipidemia, hypertriglyceridemia | Maine Center for Lipids and Cardiovascular Health | Completed | No outcome recorded |
| — | NCT00004827 | Mar 1996 → Jun 2002 | retinitis pigmentosa | Retina Foundation of the Southwest | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT03634644 Comparator | Nov 2017 → Mar 2019 | spermatogenic failure | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT03936621 Comparator | Jun 2019 → Jun 2021 | lung cancer | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2 | NCT01661764 Comparator | Feb 2013 → Dec 2016 | adenomatous colon polyp | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT01471652 Comparator | Mar 2012 → Feb 2013 | myalgic encephalomeyelitis/chronic fatigue syndrome | Columbia University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00323414 Comparator | Apr 2006 → Dec 2011 | fatty liver disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT01745263 Comparator | Dec 2012 → Nov 2017 | — | University of Zurich | Completed | No outcome recorded |
| Phase 3 | NCT00345176 Comparator | Sep 2006 → Oct 2012 | age-related macular degeneration, cataract | National Eye Institute (NEI) | Completed | No outcome recorded |
| — | NCT02137408 Comparator | Dec 2014 → Nov 2015 | hypertension, pregnancy-induced | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 52 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOCONEXENT | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | 22:6 n-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | C22:6 (n-3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | Cervonic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | DHA | “The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with...” NCT01934777 ↗26“This study aimed to compare the efficacy of docosahexaenoic acid (DHA) plus piracetam with piracetam alone in reducing the frequency and severity of BHS in infants and...” PMID 37651975 ↗ Aug 2023 “Overall, treatment data in MDD support a role for EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in combination or EPA as the omega-3 fatty acid intervention.” NCT00825994 ↗ “Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks” NCT00323414 ↗ “such as eicosapentanoic acid [EPA] and docosahexanoic acid [DHA] may reduce the risk of colorectal cancer.” NCT01661764 ↗ “5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily” NCT01814527 ↗ “treatment with docosahexaenoic acid (DHA) for 12 weeks at 1000 mg twice daily as compared to placebo” NCT01849250 ↗ “Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART” NCT02005900 ↗ “Docosahexaenoic acid (DHA) is an omega-3 fatty acid commonly found in both fish oils and algae.” NCT01903525 ↗ “Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA” NCT00976872 ↗ “Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily” NCT02137408 ↗ |
| Known as | Doconexento | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | Docosaheaenoic-acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | Docosahexaenoate | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | Docosahexaenoic Acid | “Daily supplementation with long-chain ω-3 polyunsaturated fatty acids (350-mg docosahexaenoic acid [DHA] + 650-mg eicosapentaenoic acid [EPA]), macular xanthophylls (10-mg...” PMID 24638908 ↗ May 201440“The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) and Vitamin D in children and adolescents with biopsy-proven...” NCT02098317 ↗ “Overall, treatment data in MDD support a role for EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in combination or EPA as the omega-3 fatty acid intervention.” NCT00825994 ↗ “Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks” NCT00323414 ↗ “Docosahexaenoic Acid Plus Piracetam Versus Piracetam Alone for Treatment of Breath-Holding Spells in Children: A Randomized Clinical Trial.” PMID 37651975 ↗ Aug 2023 “Lower blood levels of the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) are correlated with worse cognitive functions” PMID 37874103 ↗ 2023 “Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.” NCT03101540 ↗ “5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily” NCT01814527 ↗ “Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.” PMID 23220074 ↗ Dec 2012 “Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months” NCT02103842 ↗ “Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day” NCT05796401 ↗ |
| Known as | Docosahexaenoic acid (c22:6 n3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL367149 ↗ |
| Known as | docosahexaenoic acid (DHA) | “docosahexaenoic acid (DHA)” NCT03101527 ↗1“docosahexaenoic acid (DHA)” NCT03101540 ↗ |
| Known as | docosahexanoic acid | “The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary...” NCT01563913 ↗4“Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA” NCT00976872 ↗ |
| Action | Inhibit | “reduces normal breast tissue levels of tumor necrosis factor-alpha (TNF-alpha)” NCT01849250 ↗ |
| Modality | Other / unclassified | “algae (ocean plant) omega-3 fat supplement (DHA)” NCT00360217 ↗ |
| Route | Oral | “Oral DHA supplementation continues daily for 3 years.” NCT00004827 ↗ |
| Target | PPARG | “At a molecular level, DHA acts as a stimulator of the nuclear receptor PPAR-gamma” NCT02005900 ↗ |